Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM

被引:1
|
作者
Zach, Leor [1 ,4 ]
Agami, Amir [4 ,5 ]
Furman, Orit [1 ]
Attia, Moshe [3 ,4 ]
Cohen, Zvi [3 ,4 ]
Mizrachi, Iris Ben-Bassat [2 ]
Tam, Guy [2 ]
Zibly, Zion [3 ,4 ]
Nissim, Ouzi [3 ,4 ]
Spiegelmann, Roberto [3 ,4 ]
Huna-Baron, Ruth [2 ,4 ]
机构
[1] Sheba Med Ctr, Neurooncol Unit, Ramat Gan, Israel
[2] Sheba Med Ctr, Neuroophthalmol Serv, Ramat Gan, Israel
[3] Sheba Med Ctr, Neurosurg Dept, Ramat Gan, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Galilee Med Ctr, Nahariyya, Israel
关键词
MULTISESSION RADIOSURGERY; NORMAL TISSUE; MENINGIOMAS; TOLERANCE; NERVES;
D O I
10.1186/s13014-021-01879-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Most anterior visual pathway meningiomas (AVPM) are benign and slow-growing, but these tumors may affect visual functions, including visual acuity (VA) and visual field (VF). Due to location, most are treated non-surgically by fractionated stereotactic radiotherapy (FSRT), aiming to prevent tumor progression and visual functions deterioration. Unfortunately, FSRT in itself may affect visual functions. The current preferred treatment regimen (in terms of safety and effectiveness) is undetermined. While most cases are treated with conventional fractionation (cFSRT)-50.4-54 Gy in 28-30 fractions of 1.8-2 Gy, advances in technology have allowed shortening of total treatment length to hypofractionation (hSRT)-25-27 Gy in 3-5 fractions of 5-9 Gy. Our aim was to evaluate the association of radiotherapy regimen for treating AVPM (cFSRT vs. hSRT) with visual function outcomes (VA, VF) at the last neuro-ophthalmologic evaluation. Methods We conducted a retrospective cohort study of AVPM cases treated at Sheba Medical Center during 2004-2015. We compared cFSRT and hSRT regimens regarding visual function (VA, VF) outcomes at the last neuro-ophthalmologic evaluation. VA was determined by the logarithm of the minimum angle of resolution (LogMAR). VF was determined by the mean deviation (MD). A clinically relevant change in VA was defined as 0.2 LogMAR. Results 48 patients (13 receiving hSRT, 35 receiving cFSRT) were included, with a median follow-up of 55 months. No significant difference was evident regarding LogMAR or MD of involved eyes at the last evaluation. Six (17%) patients in the cFSRT group experienced clinically relevant VA deterioration in the involved eye, compared with six (46%) in hSRT (p = 0.06). Conclusion Our findings, using comprehensive and meticulous investigation of visual outcomes, suggest that hSRT may be associated with higher risk for VA and VF deterioration in AVPM especially in ONSM. We recommend the use of cFSRT for ONSM.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer
    Franceschini, D.
    De Rose, F.
    Cozzi, L.
    Navarria, P.
    Clerici, E.
    Franzese, C.
    Comito, T.
    Tozzi, A.
    Iftode, C.
    D'Agostino, G.
    Sorsetti, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (05) : 385 - 391
  • [42] Hypo-Fractionated Versus Conventionally Fractionated Radiotherapy for Patients with LS-SCLC: An Open-Label, Randomized, Phase 3 Trial
    Bi, N.
    Hu, X.
    Zhao, K.
    Yang, Y.
    Zhang, L.
    E, M.
    Cao, J.
    Ge, H.
    Zhu, X.
    Zhao, L.
    Di, Y.
    Jiang, W.
    Ran, J.
    Zhang, H.
    Zhang, T.
    Shen, W.
    Deng, C.
    Hu, C.
    Chen, M.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1190 - S1191
  • [43] Long term results using hypo-fractionated stereotactic radiosurgery (HFSR) for acoustic neuroma (AN)
    Lederman, G.
    Qian, G.
    Fastaia, M.
    Gilson, B.
    Cangiane, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S567 - S567
  • [44] Norm-and hypo-fractionated radiotherapy is capable of activating human dendritic cells
    Kulzer, Lorenz
    Rubner, Yvonne
    Deloch, Lisa
    Allgaeuer, Andrea
    Frey, Benjamin
    Fietkau, Rainer
    Doerrie, Jan
    Schaft, Niels
    Gaipl, Udo S.
    JOURNAL OF IMMUNOTOXICOLOGY, 2014, 11 (04) : 328 - 336
  • [45] Hypo-fractionated radiotherapy for T1 glottis carcinoma : The impact of anterior commissure involvement on the treatment outcomeS
    Shetty, Sharankumar
    Thankappan, Krishnakumar
    Anoop
    Kudpaje, Akshay
    Tkpadmanabhan
    Iyer, Subramania
    ORAL ONCOLOGY, 2013, 49 : S29 - S29
  • [46] Dosimetric and clinical analysis of pseudo-progression versus recurrence after hypo-fractionated radiotherapy for brain metastases
    Yang, Siran
    Ma, Yuchao
    Xu, Yingjie
    Liu, Qingfeng
    Zhang, Ye
    Huang, Xiaodong
    Chen, Xuesong
    Wang, Kai
    Zhao, Ruizhi
    Xiao, Jianping
    Zhang, Hongmei
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [47] Dosimetric and clinical analysis of pseudo-progression versus recurrence after hypo-fractionated radiotherapy for brain metastases
    Siran Yang
    Yuchao Ma
    Yingjie Xu
    Qingfeng Liu
    Ye Zhang
    Xiaodong Huang
    Xuesong Chen
    Kai Wang
    Ruizhi Zhao
    Jianping Xiao
    Hongmei Zhang
    Radiation Oncology, 18
  • [48] A Systematic Review of Hypo-Fractionated Radiotherapy for Localized Muscle Invasive Bladder Cancer
    Sargos, P.
    Amestoy, F.
    Fonteyne, V.
    Baumann, B. C.
    Christodouleas, J. P.
    Zilli, T.
    Hennequin, C.
    Xylinas, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E253 - E253
  • [49] Pareto Navigation Guided Automated Planning for Extreme Hypo-fractionated Prostate Radiotherapy
    Berenato, S.
    Abbott, N.
    Woodley, O.
    Chu, M.
    Palaniappan, N.
    Millin, A.
    Wheeler, P.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S432 - S433
  • [50] A pilot study: Utilization of PROMs in hypo-fractionated radiotherapy for localized prostate cancer
    Crowther, K.
    Shiels, P.
    Cole, A.
    Shepherd, P.
    Jain, S.
    Mitchell, D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S624 - S624